FDA Takes New Regulatory Action Against Ranbaxy s Paonta Sahib Plant
FDA Takes New Regulatory Action Against Ranbaxy s Paonta Sahib Plant in India
The U.S. Food and Drug Administration today announced that a facility owned by India-based Ranbaxy Laboratories falsified data and test results in approved and pending drug applications. The facility, Paonta Sahib, has been under an FDA Import Alert since September 2008.